TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”
TRxADE Health, Inc. today announced that it changed its name and ticker symbol to “Scienture Holdings, Inc.” and “SCNX”, respectively,...
Pharmaceutical
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May...
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people...
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform
Cerebrospinal fluid, cell lysates and tissue homogenates open new avenues for biomarker discovery in oncology and neurologySOUTH SAN FRANCISCO, Calif.,...
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the...
Certara’s Simcyp Consortium Celebrates 25th Anniversary
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation...
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
PITTSBURGH, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company...
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
Milestone Pharmaceuticals to Host Investor KOL Event
Learnings from the Field: Managing PSVT and Studying AFib-RVR in the Community Setting Hosted 10 am ET, Tuesday, October 8,...
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
Ahead of ADHD Awareness Month, Busy is sharing her ADHD diagnosis and Qelbree® (viloxazine extended-release capsules) treatment story to empower...
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024NEW YORK and VIENNA, Sept. 24,...
Repligen Opens Training & Innovation Center to Elevate Customer Experience
WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,...
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for...
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase...
Noom Calls for Affordable Choices and Fair Pricing of Weight-Loss Medications Ahead of Tuesday’s Senate Testimony
Noom will submit an official statement to the congressional record at Tuesday’s Senate hearing with three specific recommendations calling for...
Potential of George Medicines’ novel, low-dose, triple combination pill to transform management of hypertension highlighted at global congress
London, UK 24 September 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of...
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform...
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disordersNEW YORK,...
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept....
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company...